Company profile
ImmTune Therapies
ImmTune Therapies is engineering off-the-shelf solutions for in-body cell and gene therapy
Financial period: 1 Jul 2023 to 30 Jun 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
SH03 | Transaction MzQ0NDU2NzQ2OWFkaXF6a2N4 | Paper/PDF filed
Published 27 Nov 2024 10:47
RESOLUTIONS | Transaction QURHM1pEVTFhZGlxemtjeA | Paper/PDF filed
Published 27 Nov 2024 10:43
SH06 | Transaction MzQ0NDU2NzQ3MGFkaXF6a2N4 | Paper/PDF filed
Published 23 Nov 2024 10:58
Company registered at Companies House
1 Feb 2024 to 31 Jan 2025
Gene therapy covers a range of medicines which modify gene expression in cells to correct disease. This can be by stopping production of mutated genes, introducing normal, healthy ones or by providing completely new 'synthetic' genes. A limited set of approved gene therapies can already cure forms of blindness, muscular atrophy and cancer. It is generally...
1 Apr 2023 to 31 Mar 2024
The immune system contains many different cells with different properties, and recently, technologies have been developed that empower immune cells against specific diseases. An example where immune cells are modified to make them effectively kill cancer cells is CAR-T therapy. These therapies hold the promise of selectively destroying cancer cells by fin...
1 Jun 2022 to 31 Mar 2024
ImmTune Therapies is developing a revolutionary new method of immune cell therapy, whereby patients' cells can be genetically modified inside their bodies to endow them with cancer-fighting properties. Our first focus is in CD19 Chimeric Antigen Receptor (CAR) T-cell therapy, a game-changing cancer treatment where patient's immune cells are modified to ex...
